Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain

Applied Health Economics and Health Policy
J M Olivarese-STAR Study Group


The availability of long-acting injectable risperidone may increase adherence to antipsychotic treatment and lead to improved clinical and economic outcomes for patients with schizophrenia. To investigate the cost effectiveness of treatment with long-acting injectable risperidone compared with previous antipsychotic regimens in patients with schizophrenia enrolled in the electronic Schizophrenia Treatment Adherence Registry (e-STAR) in Spain. e-STAR is an international, long-term, ongoing, observational study of schizophrenia patients who, during their routine course of clinical practice, are started on a new antipsychotic treatment. In e-STAR, data are collected at baseline, retrospectively over a minimum period of 12 months and up to a maximum of 24 months, and prospectively at 3-month intervals for 24 months after the start of a new antipsychotic drug. For the purpose of this study, patients who started treatment with long-acting injectable risperidone during their routine clinical management and were enrolled in the e-STAR study in Spain were eligible. The effectiveness of long-acting injectable risperidone compared with previous antipsychotic treatment, defined as the absence of hospitalizations or relapses, was assessed a...Continue Reading


Nov 1, 1991·Archives of General Psychiatry·W S Fenton, T H McGlashan
Oct 6, 1999·Biological Psychiatry·E J Bromet, S Fennig
Jun 5, 2003·The American Journal of Psychiatry·John M KaneKeith Karcher
Jul 5, 2003·Current Medical Research and Opinion·Stephen D MartinB T Saleh
Oct 31, 2003·The New England Journal of Medicine·Robert Freedman
Apr 2, 2004·The British Journal of Psychiatry : the Journal of Mental Science·Stephen AlmondTraolach Brugha
Jun 3, 2004·The British Journal of Psychiatry : the Journal of Mental Science·Martin KnappPablo Lapuerta
Aug 5, 2004·Psychiatric Services : a Journal of the American Psychiatric Association·Hui-Chu Lang, Tung-Pine Su
Jun 25, 2005·Schizophrenia Bulletin·Evelyn J BrometMarsha Tanenberg-Karant
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Sep 29, 2005·The Journal of Clinical Psychiatry·Eric Q WuJyoti Aggarwal
Dec 22, 2005·Current Medical Research and Opinion·R GoereeJ-E Tarride
Feb 10, 2006·Current Medical Research and Opinion·Eduard Parellada
Jul 20, 2006·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Juan Oliva-MorenoBeatriz Duque-González
May 24, 2007·Journal of Evaluation in Clinical Practice·Mark Bounthavong, Mark P Okamoto
Dec 15, 2007·Journal of the International Neuropsychological Society : JINS·Sophie RémillardHenri Cohen

❮ Previous
Next ❯


Aug 27, 2013·Applied Health Economics and Health Policy·Jan ZeidlerStephan Heres
Jun 6, 2009·International Journal of Clinical Practice·K S AkhrasJ M Palumbo
Oct 17, 2009·Expert Review of Neurotherapeutics·Jesús De la GándaraJosé Antonio Burón
Jul 21, 2012·Expert Review of Pharmacoeconomics & Outcomes Research·Pierre Chue, James Chue
Sep 20, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Anders GustavssonUNKNOWN CDBE2010Study Group
Mar 21, 2012·Nordic Journal of Psychiatry·Luis SanMario Peña
Aug 19, 2014·PloS One·Oleguer Parés-BadellJordi Alonso
Jun 17, 2016·Journal of Clinical Psychopharmacology·Saínza GarcíaAna González-Pinto
Apr 28, 2018·Journal of Mental Health·Rosarin SruamsiriJörg Mahlich
Feb 20, 2015·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Marie-Hélène LafeuillePatrick Lefebvre
Sep 2, 2010·Applied Health Economics and Health Policy·Marja HensenBen van Hout
May 8, 2010·CNS Spectrums·José Ramón Gutiérrez-CasaresDavid Alonso-Escolano
Aug 16, 2013·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Rahul ManchandaNicola Banks

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here